SG11201509259RA - Bispecific constructs and their use in the treatment of various diseases - Google Patents
Bispecific constructs and their use in the treatment of various diseasesInfo
- Publication number
- SG11201509259RA SG11201509259RA SG11201509259RA SG11201509259RA SG11201509259RA SG 11201509259R A SG11201509259R A SG 11201509259RA SG 11201509259R A SG11201509259R A SG 11201509259RA SG 11201509259R A SG11201509259R A SG 11201509259RA SG 11201509259R A SG11201509259R A SG 11201509259RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- various diseases
- bispecific constructs
- bispecific
- constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002500 | 2013-05-10 | ||
| PCT/EP2014/001282 WO2014180577A1 (en) | 2013-05-10 | 2014-05-12 | Bispecific constructs and their use in the treatment of various diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509259RA true SG11201509259RA (en) | 2015-12-30 |
Family
ID=48463668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509259RA SG11201509259RA (en) | 2013-05-10 | 2014-05-12 | Bispecific constructs and their use in the treatment of various diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10077312B2 (en) |
| EP (2) | EP3415534A1 (en) |
| JP (1) | JP2016519135A (en) |
| KR (1) | KR20160007604A (en) |
| CN (1) | CN105408356A (en) |
| AU (2) | AU2014264951A1 (en) |
| CA (2) | CA2911946A1 (en) |
| HK (1) | HK1215868A1 (en) |
| SG (1) | SG11201509259RA (en) |
| WO (1) | WO2014180577A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298041A1 (en) * | 2015-05-18 | 2018-03-28 | Numab Therapeutics AG | Novel treatment methods based on multifunctional molecules |
| AU2016278586B2 (en) * | 2015-06-15 | 2022-05-19 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format |
| CA3053242A1 (en) | 2016-02-19 | 2017-08-24 | Dignity Health | Antibody fusion protein and related compositions for targeting cancer |
| CA3032304A1 (en) * | 2016-07-29 | 2018-02-01 | New York University | Gamma delta t cells as a target for treatment of solid tumors |
| CN108264560B (en) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | Bifunctional molecule combining CD3 and CD28 and application thereof |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| KR20240060739A (en) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Proteins binding her2, nkg2d and cd16 |
| EP3619229A4 (en) * | 2017-05-02 | 2021-05-26 | Dana-Farber Cancer Institute, Inc. | Il-23r antagonists to reprogram intratumoral t regulatory cells into effector cells |
| KR20200063147A (en) * | 2017-10-10 | 2020-06-04 | 누맙 세러퓨틱스 아게 | PDL1 targeting antibodies and methods of use thereof |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| MX2020008336A (en) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor. |
| EP3774907A1 (en) * | 2018-04-13 | 2021-02-17 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| CA3127103A1 (en) | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| US20230058276A1 (en) * | 2020-01-24 | 2023-02-23 | Amgen Inc. | Methods for harvesting biomolecules |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (en) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | Chimeric antigen receptor system with adaptable receptor specificity |
| EP4384597A1 (en) * | 2021-08-11 | 2024-06-19 | Cytoarm Co. Ltd. | Process for producing armed immune cells |
| AU2023265474A1 (en) * | 2022-05-06 | 2024-10-31 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19725586C2 (en) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies |
| KR100508289B1 (en) * | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 specific polypeptides and uses thereof |
| DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
| CN101824088B (en) | 2002-10-30 | 2012-05-30 | 健泰科生物技术公司 | Inhibition of il-17 production |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| WO2007033230A2 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-cd3 antibody formulations |
| LT2548577T (en) | 2005-12-29 | 2017-04-10 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
| KR20100014568A (en) | 2007-02-28 | 2010-02-10 | 쉐링 코포레이션 | Engineered anti-il-23r antibodies |
| EP2417974A1 (en) * | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
| ES2593484T3 (en) * | 2007-03-29 | 2016-12-09 | Genmab A/S | Bispecific antibodies and their production methods |
-
2014
- 2014-05-12 EP EP18182443.4A patent/EP3415534A1/en not_active Withdrawn
- 2014-05-12 AU AU2014264951A patent/AU2014264951A1/en not_active Abandoned
- 2014-05-12 WO PCT/EP2014/001282 patent/WO2014180577A1/en active Application Filing
- 2014-05-12 JP JP2016512252A patent/JP2016519135A/en active Pending
- 2014-05-12 CA CA2911946A patent/CA2911946A1/en not_active Abandoned
- 2014-05-12 SG SG11201509259RA patent/SG11201509259RA/en unknown
- 2014-05-12 KR KR1020157035109A patent/KR20160007604A/en not_active Application Discontinuation
- 2014-05-12 CN CN201480026690.6A patent/CN105408356A/en active Pending
- 2014-05-12 US US14/889,225 patent/US10077312B2/en active Active
- 2014-05-12 EP EP14728087.9A patent/EP2994490A1/en not_active Ceased
- 2014-11-03 CA CA2948686A patent/CA2948686A1/en not_active Abandoned
- 2014-11-03 AU AU2014393729A patent/AU2014393729A1/en not_active Abandoned
-
2015
- 2015-05-18 US US14/715,398 patent/US20150329637A1/en not_active Abandoned
-
2016
- 2016-04-04 HK HK16103786.4A patent/HK1215868A1/en unknown
-
2018
- 2018-05-14 US US15/978,390 patent/US20180282419A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180282419A1 (en) | 2018-10-04 |
| JP2016519135A (en) | 2016-06-30 |
| US20160083473A1 (en) | 2016-03-24 |
| EP2994490A1 (en) | 2016-03-16 |
| US10077312B2 (en) | 2018-09-18 |
| CA2948686A1 (en) | 2015-11-19 |
| HK1215868A1 (en) | 2016-09-23 |
| KR20160007604A (en) | 2016-01-20 |
| AU2014264951A1 (en) | 2015-11-12 |
| WO2014180577A1 (en) | 2014-11-13 |
| CA2911946A1 (en) | 2014-11-13 |
| US20150329637A1 (en) | 2015-11-19 |
| CN105408356A (en) | 2016-03-16 |
| AU2014393729A1 (en) | 2016-12-01 |
| EP3415534A1 (en) | 2018-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215868A1 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| HK1216251A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| IL260511B (en) | Prodrugs of fumarates and their use in treating various diseases | |
| HK1217021A1 (en) | Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1 csf-1r pd-l1 | |
| HK1222530A1 (en) | Microclosures and related methods for skin treatment | |
| HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| EP2999474A4 (en) | Therapeutic and method of use | |
| PL3004112T3 (en) | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | |
| PT3004108T (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | |
| PL3466425T3 (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL239904A0 (en) | Inhibitory oligonucleotides and their use in therapy | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| HK1223041A1 (en) | Pidotimod for use in the treatment of inflammation-associated diseases | |
| EP2744786A4 (en) | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| EP2981324A4 (en) | Methods and articles of manufacture for the treatment of skin | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| HK1209073A1 (en) | Plod-2 stimulators and their use in the treatment of skin plod-2 | |
| EP2970152A4 (en) | Preparation and method for use in the treatment of respiratory diseases | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use |